|Bid||11.31 x 3000|
|Ask||11.96 x 1000|
|Day's Range||11.10 - 11.38|
|52 Week Range||10.13 - 14.27|
|Beta (5Y Monthly)||1.18|
|PE Ratio (TTM)||3.51|
|Earnings Date||Feb 15, 2022 - Feb 21, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.00|
BOSTON, May 25, 2022--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, presented new findings during the 2022 Digestive Disease Week® (DDW) meeting that suggest colonic IW-3300 has the potential to help manage abdominopelvic visceral pain in patients with disorders of gut-brain interaction (DGBI) and related visceral pain disorders. The oral presentation, titled Colon-Targeted Delivery Of Guanylate Cyclase-C Agonist IW-3300 Relieves Comorbid Chronic Pelvic And Soma
BOSTON, May 09, 2022--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that the company and its collaborators will present eight studies, including two oral presentations, during the Digestive Disease Week® (DDW) 2022 meeting being held from May 21 through May 24, 2022 in San Diego, CA.
Ironwood (IRWD) witnesses strong year-over-year sales growth on continued demand for Linzess. Its first-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines.